Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company.

Six of 93 patients (6 percent) in the placebo group and 6 of 182 patients (3 percent) in the combined REGN-COV2 group had a medically attended visit, a relative difference of approximately 49 percent, the research team reported last week in the New England Journal of Medicine.

The cocktail reduced viral load “with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline,” the researchers said. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group.

The FDA granted Regeneron’s antibody cocktail Emergency Use Authorization in November.